

CLAIMS

1. A conjugate, or a pharmaceutically acceptable salt thereof, described by formula (M-I):



(M-I)

wherein A^1 has the structure of formula (A):





(A)

m is 0, 1, 2, 3, 4, 5, or 6;

s is 0 or 1;

each of X^1, X^2, X^3, X^4, X^5, and X^6 is, independently, N, CR^4, or C-Y-R^5, wherein at least one of X^1, X^2, X^3, X^4, X^5, and X^6 is C-Y-R^5 and R^5 is a bond to L;

R^1 is  or ;

Z is O, S, or sulfonyl;

each of R^{2a} and R^{2b} is, independently, H, optionally substituted C_1-C_{20} alkyl, optionally substituted C_2-C_{20} alkenyl, optionally substituted C_2-C_{20} alkynyl, optionally substituted C_1-C_{20} heteroalkyl, optionally substituted C_2-C_{20} heteroalkenyl, optionally substituted C_2-C_{20} heteroalkynyl, optionally substituted C_3-C_{20} cycloalkyl, optionally substituted C_3-C_{20} cycloalkenyl, optionally substituted C_2-C_{20} heterocycloalkyl, optionally substituted C_2-C_{20} heterocycloalkenyl, optionally substituted C_6-C_{18} aryl, or optionally substituted C_2-C_{19} heteroaryl;

each R^3 is, independently, OH, SH, halogen, optionally substituted amino, optionally substituted C_1-C_{20} alkyl, optionally substituted C_2-C_{20} alkenyl, optionally substituted C_2-C_{20} alkynyl, optionally substituted C_1-C_{20} heteroalkyl, optionally substituted C_2-C_{20} heteroalkenyl, optionally substituted C_2-C_{20} heteroalkynyl, optionally substituted C_3-C_{20} cycloalkyl, optionally substituted C_3-C_{20} cycloalkenyl, optionally substituted C_2-C_{20} heterocycloalkyl, optionally substituted C_2-C_{20} heterocycloalkenyl, optionally substituted C_6-C_{18} aryl, or optionally substituted C_2-C_{19} heteroaryl;

R^4 is H, halogen, OH, SH, optionally substituted amino, optionally substituted C_1-C_{20} alkyl, optionally substituted C_2-C_{20} alkenyl, optionally substituted C_2-C_{20} alkynyl, optionally substituted C_1-C_{20}

heteroalkyl, optionally substituted C_2-C_{20} heteroalkenyl, optionally substituted C_2-C_{20} heteroalkynyl, optionally substituted optionally substituted C_3-C_{20} cycloalkyl, optionally substituted C_3-C_{20} cycloalkenyl, optionally substituted C_2-C_{20} heterocycloalkyl, optionally substituted C_2-C_{20} heterocycloalkenyl, optionally substituted C_6-C_{18} aryl, or optionally substituted C_2-C_{19} heteroaryl;

each of R^{6a} and R^{6b} is, independently, H, optionally substituted C_1-C_{20} alkyl, optionally substituted C_2-C_{20} alkenyl, optionally substituted C_2-C_{20} alkynyl, optionally substituted C_1-C_{20} heteroalkyl, optionally substituted C_2-C_{20} heteroalkenyl, optionally substituted C_2-C_{20} heteroalkynyl, optionally substituted C_3-C_{20} cycloalkyl, optionally substituted C_3-C_{20} cycloalkenyl, optionally substituted C_2-C_{20} heterocycloalkyl, optionally substituted C_2-C_{20} heterocycloalkenyl, optionally substituted C_6-C_{18} aryl, or optionally substituted C_2-C_{19} heteroaryl;

Y is a first linker;

L is a second linker;


n is 1 or 2;

each E comprises an Fc domain monomer;

T is an integer from 1 to 20; and

the squiggly line indicates that L is covalently attached to E.

2. The conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein A^1 has the structure of formula (A-Ib):



(A-Ib)

3. The conjugate of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein s is 0.

4. The conjugate of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein each of R^{2a} and R^{2b} is, independently, H, optionally substituted C_1-C_{20} alkyl, or optionally substituted C_1-C_{20} heteroalkyl.


5. The conjugate of claim 4, or a pharmaceutically acceptable salt thereof, wherein each of R^{2a} and R^{2b} is H.

6. The conjugate of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R^4 is H, halogen, OH, SH, optionally substituted amino, optionally substituted C_1-C_{20} alkyl, or optionally substituted C_1-C_{20} heteroalkyl.

7. The conjugate of claim 6, or a pharmaceutically acceptable salt thereof, wherein R^4 is halogen.

8. The conjugate of claim 7, or a pharmaceutically acceptable salt thereof, wherein R^4 is Cl.

9. The conjugate of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein R^1 is




.

10. The conjugate of claim 9, or a pharmaceutically acceptable salt thereof, wherein each of R^{6a} and R^{6b} is, independently, H, optionally substituted C_1-C_{20} alkyl, or optionally substituted C_1-C_{20} heteroalkyl.

11. The conjugate of claim 10, or a pharmaceutically acceptable salt thereof, wherein each of R^{6a} and R^{6b} is, independently, H, $-CH_3$, $-CH_2CH_3$, $-CH_2OH$, $-CH_2OCH_3$ $-CH_2CH_2OH$, or $-CH_2CH_2OCH_3$.

12. The conjugate of claim 11, or a pharmaceutically acceptable salt thereof, wherein each of R^{6a} and R^{6b} is H.

13. The conjugate of any one of claims 1-12, wherein Y is:




each of p1, p2, p3, and p4 is, independently, 0, 1, 2, 3, or 4;

q is 0, 1, 2, 3, or 4;

each X^7 is, independently, N or CH;

each X^8 is, independently, O, NH, CH_2, or C(=O);


R^{N1} is H, optionally substituted C_1-C_{20} alkyl, optionally substituted C_2-C_{20} alkenyl, optionally substituted C_2-C_{20} alkynyl, optionally substituted C_1-C_{20} heteroalkyl, optionally substituted C_2-C_{20} heteroalkenyl, optionally substituted C_2-C_{20} heteroalkynyl, optionally substituted C_3-C_{20} cycloalkyl, optionally substituted C_3-C_{20} cycloalkenyl, optionally substituted C_2-C_{20} heterocycloalkyl, optionally substituted C_2-C_{20} heterocycloalkenyl, optionally substituted C_6-C_{18} aryl, optionally substituted C_2-C_{19} heteroaryl, optionally substituted C_1-C_{20} alkaryl, or optionally substituted C_1-C_{20} alkylcycloalkyl;

each R^7 is, independently, , optionally substituted C_3-C_{20} cycloalkyl, optionally substituted C_3-C_{20} cycloalkenyl, optionally substituted C_2-C_{20} heterocycloalkyl, or optionally substituted C_2-C_{20} heterocycloalkenyl;


each of R^{7a} and R^{7b} is, independently, H, optionally substituted C_1-C_{20} alkyl, optionally substituted C_2-C_{20} alkenyl, optionally substituted C_2-C_{20} alkynyl, optionally substituted C_1-C_{20} heteroalkyl, optionally substituted C_2-C_{20} heteroalkenyl, optionally substituted C_2-C_{20} heteroalkynyl, optionally substituted C_3-C_{20} cycloalkyl, optionally substituted C_3-C_{20} cycloalkenyl, optionally substituted C_2-C_{20} heterocycloalkyl, optionally substituted C_2-C_{20} heterocycloalkenyl, optionally substituted C_6-C_{18} aryl, or optionally substituted C_2-C_{19} heteroaryl; and

each R^8 is, independently, halogen, OH, SH, optionally substituted amino, optionally substituted C_1-C_{20} alkyl, optionally substituted C_2-C_{20} alkenyl, optionally substituted C_2-C_{20} alkynyl, optionally substituted C_1-C_{20} heteroalkyl, optionally substituted C_2-C_{20} heteroalkenyl, optionally substituted C_2-C_{20} heteroalkynyl, optionally substituted C_3-C_{20} cycloalkyl, optionally substituted C_3-C_{20} cycloalkenyl, optionally substituted C_2-C_{20} heterocycloalkyl, optionally substituted C_2-C_{20} heterocycloalkenyl, optionally substituted C_6-C_{18} aryl, or optionally substituted C_2-C_{19} heteroaryl.

14. The conjugate of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein Y is

 or .

15. The conjugate of claim 14, or a pharmaceutically acceptable salt thereof, wherein Y is



16. The conjugate of any one of claims 1-15, or a pharmaceutically acceptable salt thereof, wherein L comprises one or more optionally substituted C_1-C_{40} alkylene, optionally substituted C_1-C_{40} heteroalkylene, optionally substituted C_1-C_{40} alkoxylene, optionally substituted C_2-C_{20} alkenylene, optionally substituted C_2-C_{20} heteroalkenylene, optionally substituted C_2-C_{20} alkynylene, optionally substituted C_2-C_{20} heteroalkynylene, optionally substituted C_3-C_{20} cycloalkylene, optionally substituted C_2-C_{20} heterocycloalkylene, optionally substituted C_4-C_{20} cycloalkenylene, optionally substituted C_4-C_{20} heterocycloalkenylene, optionally substituted C_8-C_{20} cycloalkynylene, optionally substituted C_8-C_{20} heterocycloalkynylene, optionally substituted C_5-C_{15} arylene, optionally substituted C_2-C_{15} heteroarylene, O, S, NR^i, P, carbonyl, thiocarbonyl, sulfonyl, phosphate, phosphoryl, or imino,

wherein R^i is H, optionally substituted C_1-C_{20} alkyl, optionally substituted C_1-C_{20} heteroalkyl, optionally substituted C_2-C_{20} alkenyl, optionally substituted C_2-C_{20} heteroalkenyl, optionally substituted C_2-C_{20} alkynyl, optionally substituted C_2-C_{20} heteroalkynyl, optionally substituted C_3-C_{20} cycloalkyl, optionally substituted C_2-C_{20} heterocycloalkyl, optionally substituted C_4-C_{20} cycloalkenyl, optionally substituted C_4-C20 heterocycloalkenyl, optionally substituted C_8-C_{20} cycloalkynyl, optionally substituted C_8-C_{20} heterocycloalkynyl, optionally substituted C_5-C_{15} aryl, or optionally substituted C_2-C_{15} heteroaryl.

17. The conjugate of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein L is oxo substituted.

18. The conjugate of any one of claims 1-17, or a pharmaceutically acceptable salt thereof, wherein the backbone of L comprises between 1 and 250 atoms.

19. The conjugate of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein L is described by the formula:

$$J^1\text{-}(Q^1)_g\text{-}(T^1)_h\text{-}(Q^2)_i\text{-}(T^2)_j\text{-}(Q^3)_k\text{-}(T^3)_l\text{-}(Q^4)_m\text{-}(T^4)_n\text{-}(Q^5)_o\text{-}J^2$$

wherein J^1 is a bond attached to A^1;

J^2 is a bond attached to E;


each of Q^1, Q^2, Q^3, Q^4, and Q^5 is, independently, optionally substituted C1-C40 alkylene, optionally substituted C1-C40 heteroalkylene, optionally substituted C1-C40 alkoxylene, optionally substituted C2-C20 alkenylene, optionally substituted C2-C20 heteroalkenylene, optionally substituted C2-C20 alkynylene, optionally substituted C2-C20 heteroalkynylene, optionally substituted C3-C20 cycloalkylene, optionally substituted C_2-C_{20} heterocycloalkylene, optionally substituted C4-C20 cycloalkenylene, optionally substituted C4-C20 heterocycloalkenylene, optionally substituted C8-C20 cycloalkynylene, optionally substituted C8-C20 heterocycloalkynylene, optionally substituted C5-C15 arylene, or optionally substituted C2-C15 heteroarylene;

each of T^1, T^2, T^3, and T^4 is, independently, O, S, NR^i, P, carbonyl, thiocarbonyl, sulfonyl, phosphate, phosphoryl, imino, or oximo;

R^i is H, optionally substituted C1-C20 alkyl, optionally substituted C1-C20 heteroalkyl, optionally substituted C2-C20 alkenyl, optionally substituted C2-C20 heteroalkenyl, optionally substituted C2-C20 alkynyl, optionally substituted C2-C20 heteroalkynyl, optionally substituted C3-C20 cycloalkyl, optionally substituted C_2-C_{20} heterocycloalkyl, optionally substituted C4-C20 cycloalkenyl, optionally substituted C4-C20 heterocycloalkenyl, optionally substituted C8-C20 cycloalkynyl, optionally substituted C8-C20 heterocycloalkynyl, optionally substituted C5-C15 aryl, or optionally substituted C2-C15 heteroaryl; and

each of g, h, i, j, k, l, m, n, and o is, independently, 0, 1, or 2.

20. The conjugate of claim 19, or a pharmaceutically acceptable salt thereof, wherein Q^1 is



21. The conjugate of claim 19 or 20, or a pharmaceutically acceptable salt thereof, wherein Q^2 is optionally substituted C_1-C_{40} alkylene, optionally substituted C_1-C_{40} heteroalkylene, optionally substituted C_1-C_{40} alkoxylene, or optionally substituted C_2-C_{15} heteroarylene.

22. The conjugate of any one of claims 19-21, or a pharmaceutically acceptable salt thereof, wherein Q^3 is optionally substituted C_2-C_{15} heteroarylene.

23. The conjugate of any one of claims 19-22, or a pharmaceutically acceptable salt thereof, wherein Q^4 is optionally substituted C_1-C_{40} alkylene, optionally substituted C_1-C_{40} heteroalkylene, or optionally substituted C_1-C_{40} alkoxylene.

24. A conjugate, or a pharmaceutically acceptable salt thereof, described by a formula of Table 2.

25. The conjugate of any one of claims 1-24, or a pharmaceutically acceptable salt thereof, wherein the squiggly line connected to E indicates that the L of A^1-L is covalently attached to a nitrogen atom of a solvent-exposed lysine of E.

26. The conjugate of any one of claim 1-24, or a pharmaceutically acceptable salt thereof, wherein the squiggly line connected to E indicates that the L of each A^1-L is covalently attached to the sulfur atom of a solvent-exposed cysteine of E.

27. The conjugate of any one of claims 1-24, or a pharmaceutically acceptable salt thereof, wherein n is 2, and each E dimerizes to form an Fc domain.

28. The conjugate of any one of claims 1-27, or a pharmaceutically acceptable salt thereof, wherein each E is a human IgG1 Fc domain monomer.

29. The conjugate of any one of claims 1-28, or a pharmaceutically acceptable salt thereof, wherein each E comprises a substitution mutation at N297 selected from N297A, N297G, or N297Q, wherein the amino acid numbering of each Fc domain monomer is according to the Kabat EU index.

30. The conjugate of any one of claims 1-29, or a pharmaceutically acceptable salt thereof, wherein each E comprises a C220S substitution mutation, wherein the amino acid numbering of each Fc domain monomer is according to the Kabat EU index.

31. The conjugate of any one of claims 1-30, or a pharmaceutically acceptable salt thereof, wherein each E comprises the amino acid sequence of any one of SEQ ID NOs: 1-112 or 115-120.

32. The conjugate of claim 31, or a pharmaceutically acceptable salt thereof, wherein each E comprises the sequence of SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 116, or SEQ ID NO: 120.

33. The conjugate of any one of claims 1-32, or a pharmaceutically acceptable salt thereof, wherein T is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

34. A population of conjugates of any one of claims 1-33, or a pharmaceutically acceptable salt thereof, wherein the average value of T is 1 to 10.

35. A population of conjugates of claim 34, or a pharmaceutically acceptable salt thereof, wherein the average value of T is 1 to 5.

36. A pharmaceutical composition comprising a conjugate or a population of conjugates of any one of claims 1-35, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

37. Use of a conjugate, population of conjugates, or pharmaceutical composition of any one of claims 1-36 in the manufacture of a medicament for treating a subject having cancer.

38. The use of claim 37, wherein the cancer is selected from lung cancer, optionally non-small cell lung cancer or small-cell lung cancer; head and neck cancer, optionally squamous cell carcinoma; renal cell carcinoma; breast cancer; ovarian cancer; pancreatic cancer; colorectal cancer; urothelial cancer; bile duct cancer; endometrial cancer; melanoma; or esophageal cancer.

39. The use of claim 37 or 38, wherein the cancer is a solid tumor.

40. The use of any one of claims 37-39, wherein the cancer overexpresses or is known to overexpress CD73 relative to a non-cancerous cell of the same tissue type.

41. The use of any one of claims 37-40, wherein the medicament is to be further administered with an immune checkpoint inhibitor.

42. The use of claim 41, wherein the immune checkpoint inhibitor is a PD-1 inhibitor.

43. The use of any one of claims 37-42, wherein the conjugate, population of conjugates, or pharmaceutical composition is to be administered intramuscularly, intravenously, intradermally, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostatically, intrapleurally, intratracheally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, peritoneally, subcutaneously, subconjunctival, intravesicularlly, mucosally, intrapericardially, intraumbilically, intraocularally, orally, locally, by inhalation, by injection, or by infusion.